In biotechnology, we expect both vertical integration and building of scale to lead to more M&A. So we expect a very busy first half of the year, both in issuance and M&A. We expect the presidential elections to create incremental volatility throughout the year, which will start to pick up in the second half of the year. We saw great investor receptivity to transformational M&A in 2019 and expect the low volatility backdrop of the equity capital markets to be very fertile ground. In M&A, we saw a number of transformational deals that we expect will continue in 2020. Which is rare to have all three sectors performing as strongly as they did in ECM space. We had really strong equity issuance in both biotech, medical technology, and healthcare services. Mike: We expect 2020 to be another exciting year in healthcare coming off of a very strong 2019.

I look where we are today, we've got internal pipelines that are in much better position than they've been historically, and we've had this wave of new smaller companies with really interesting science.Īnd on top of that, we've had an FDA that has looked to really partner with the industry, especially look at some of these very differentiated new products coming to market where you maybe need different endpoints or pathways than existed historically. If we think about the last patent cycle, it had almost no pipeline, you had very few of these smaller biotech companies that you could look to partner with or outright acquire. Think about the pharma industry longer term, we do have another major patent cycle we're gonna have to deal with starting in 2025. We're seeing much more constructive dialogue between not just the pharma companies developing drugs, but the pharma companies engaging with payers and really making sure not that the drug is approved, but also that the patient can afford it and get access to the product as well.

Patients are being increasingly aware and exposed to the cost of medication. Patient affordability is really front and center in almost every conversation, whether it's a pharma company or a biotech company these days. You need to make sure that the patients get access to the product, that they can afford the product. What we see that translates to is a continued robust pipeline of new products going into the FDA and really nice outcomes for patients as we start to address a lot of these disease states that haven't really had great solutions historically. We're really seeing the industry harnessing new technologies, whether that's gene therapy, cell therapy, bispecific antibodies, and harnessing those technologies to really meet unmet need in the industry. I think that those are the things that we'll see come to the market over the next several years.Ĭhris: Heading into 2020, we see really a continuation of some very positive trends that we've seen for the last few years. You might be halfway around the world and the ability to be able to access that. As we think about things like blockchain technology, the ability to be able to take your medical records with you wherever you go. For example, in oncology, where you can gather information in a short period of time, make that diagnosis from a clinical perspective and really get the patient on the right treatment protocol. They'll look it up, they'll say, 'Is there a clinic near me 'to be able to get the services that I want?'Īs we think about the future of technology, we think about things like artificial intelligence. So, we think about them getting most of their information from a handheld device. Millennials and Generation X'ers, most of them don't have a primary care doctor today. Three, it's through data analytics where you're sharing that back with the member. It's two, things like Telehealth and Telemedicine reaching that patient where they want to be reached. It's one, making it easier, for example, to check into the physician’s office. So, you're really, as a consumer, thinking about how do I want to spend those dollars? Where am I going to get the best outcome for the lowest cost? When we think about companies using technology to really enhance the consumer experience, it's really across the board. Today, your out-of-pocket costs on average are north of $2,000. And so, as we think about the disruptions that are happening in the marketplace, we think that drug retails have the opportunity to utilize that footprint that they have today to provide more services. The consumer wants their services where they want them, when they want them, at the lowest price. Lisa: The consumer's the biggest disruptor in healthcare.

Credit insights